Generic Epclusa (Sofosbuvir/Velpatasvir)

Epclusa is Gilead's brand name for sofosbuvir/velpatasvir, a pan-genotypic direct-acting antiviral for chronic hepatitis C. Generic sofosbuvir/velpatasvir contains the same active ingredients at the same strength and can clear most chronic infections over a 12-week course, at a far lower cost than brand Epclusa. Used as prescribed by a licensed medical professional.

Epclusa is the originator brand of sofosbuvir/velpatasvir, developed by Gilead Sciences to treat chronic hepatitis C. It combines two direct-acting antivirals in one fixed-dose tablet and is described as pan-genotypic, meaning it is used across all major hepatitis C genotypes. Generic sofosbuvir/velpatasvir, produced by licensed pharmaceutical manufacturers, contains the identical active ingredients at the same 400 mg/100 mg strength. Treatment is always started and supervised by a hepatologist or other qualified clinician.

Sofosbuvir/velpatasvir works by targeting two separate proteins the hepatitis C virus needs to copy itself. Sofosbuvir blocks the NS5B polymerase, an enzyme that builds new viral genetic material, while velpatasvir inhibits the NS5A protein involved in viral assembly and replication. By interrupting both steps at once, the combination suppresses the virus across genotypes over a defined course. Because dosing and suitability depend on liver health and prior treatment, therapy must be prescribed and monitored by a licensed clinician.

Sofosbuvir/velpatasvir may be considered for adults with chronic hepatitis C, including several genotypes and certain patients with compensated liver disease, when a specialist judges it appropriate. Suitability depends on factors such as genotype, degree of liver scarring, prior antiviral treatment, other medicines being taken and overall health. It is not suitable for everyone, and some drug interactions require caution. A hepatologist or hepatitis specialist decides whether this treatment is right for an individual and supervises the full course.

The usual dose of sofosbuvir/velpatasvir is one fixed-dose tablet containing sofosbuvir 400 mg and velpatasvir 100 mg, taken once daily for 12 weeks, with or without food. Some patients, such as those with advanced liver disease, may need additional medicines or adjusted management as decided by a specialist. The full course must be completed exactly as prescribed by a licensed medical professional; this information is educational and not a substitute for your prescriber's instructions.

Never change your dose on your own.

The most commonly reported side effects of sofosbuvir/velpatasvir include headache, fatigue and nausea, which are usually mild. Less commonly, patients may notice weakness or difficulty sleeping. Serious slowing of the heart rate has been reported when this medicine is taken with amiodarone, so that combination is generally avoided. Anyone who has had hepatitis B needs monitoring, as it can reactivate. Report any severe or persistent symptoms to your prescriber, who supervises treatment throughout the course.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Sofosbuvir/velpatasvir is one of several direct-acting antiviral combinations used for chronic hepatitis C. Others include glecaprevir/pibrentasvir and sofosbuvir/ledipasvir, each with its own genotype coverage, course length and interaction profile. The main draw of sofosbuvir/velpatasvir is that it is pan-genotypic and taken as a single daily tablet, which can simplify treatment. Choosing between these regimens is a clinical decision based on genotype, liver condition and prior therapy, not a swap patients should make themselves.

Brand Epclusa carries a high price because Gilead funded the original research, trials and regulatory approval and holds market exclusivity in wealthier countries, which keeps Epclusa cost near the top of hepatitis C pricing. Once approved manufacturers can produce the same molecule, competition drives the price down sharply. Generic sofosbuvir/velpatasvir uses the identical active ingredients at the same strength but without the originator premium, which is why generic Epclusa is substantially cheaper per 12-week course while remaining a prescription medicine taken under supervision.

A typical course is one tablet daily for 12 weeks, taken consistently to keep viral suppression steady. Your clinician arranges baseline and follow-up blood tests, including a check of the virus around 12 weeks after finishing to confirm whether the infection has been cleared. Common side effects such as headache, fatigue and nausea are usually mild. Tell your prescriber about all other medicines, as some interact with this combination. Never stop early or adjust the dose without medical advice.